1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Verisante Technology Inc.

Verisante Technology Inc.

VRSEF
Verisante Technology Inc.US flagOther OTC
0.00
USD
- -
- -
314,103.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.11
0.03
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.54
-0.68
-0.4
-0.26
-0.17
-0.24
0.04
- -
-0.02
0.07
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.49
-0.63
-0.19
-0.09
-0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.67
-2.17
-2.32
-0.42
-0.56
-0.77
-0.71
-0.72
-0.74
-0.3
-0.15
-0.12
-0.11
-0.12
Tangible Book Value per Share
0.34
0.15
0.02
-0.09
-0.15
-0.26
-0.13
-0.14
-0.16
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
7
7
8
9
9
10
10
10
10
17
34
43
44
44
Sales/Revenue/Turnover
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-633.18
-1,525.75
-1,730.27
-5,747.53
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-5
-3
-2
-2
-2
- -
- -
- -
1
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-631.51
-1,477.68
-1,719
-6,218.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
2
1
- -
- -
-1
-2
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
6
5
3
1
- -
-2
-1
-1
-2
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-6.3
- -
- -
-19.49
- -
- -
-0.62
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
44
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
118.55%
104.34%
-44.54%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-84.33%
-119.14%
-127.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Thomas A. Braun
Full Time Employees
18
Sector
Healthcare
Industry
Medical - Devices
Address
422 Richards Street Vancouver BC Canada V6B
IPO Date
May 6, 2011
Website
verisante.com
Similar Companies
Acutus Medical, Inc. (AFIB)
TruScreen Group Limited (TRU.AX)
Abiomed, Inc. (ABMD)
FUJIFILM Holdings Corporation (FUJIF)
VentriPoint Diagnostics Ltd. (VPT.V)
IRIDEX Corporation (IRIX)
Business
Verisante Technology Inc. (TSX-V: VER.H; OTC: VRSEF) operates as a capital pool company seeking reverse takeover transactions with life sciences firms demonstrating growth potential. The company maintains no active operations beyond identifying and pursuing qualifying acquisitions, primarily targeting medical device, pharmaceutical, and biotechnology segments; it previously focused on commercializing non-invasive cancer detection systems such as Raman spectroscopy-based skin cancer scanners but has shifted entirely to its qualifying transaction mandate. Headquartered in Vancouver, British Columbia, Canada, and founded in 2006, Verisante conducts its search activities across North America with a focus on innovative healthcare solutions. In August 2024, Verisante entered a binding letter of intent to acquire 100% of SunRegen Healthcare AG, a Basel, Switzerland-based pharmaceutical developer of SBC003, a patented neuroprotection compound targeting ophthalmic neurodegenerative diseases like retinitis pigmentosa and expanding to CNS disorders; the proposed reverse takeover advanced through October 2024 with legal drafting, financial audits, and a $2.1 million pre-RTO private placement closed by SunRegen in December 2024. However, the parties mutually terminated the letter of intent on March 28, 2025, halting the transaction pending due diligence completion, TSX Venture Exchange approval, and regulatory clearances. Verisante continues its pursuit of alternative life sciences targets without current partnerships, funding rounds, or product launches beyond this discontinued effort.

Company News

APIChat

  • accessnewswire.com

    Verisante Technology, Inc. Announces Termination of Proposed RTO with SunRegen Healthcare AG

  • accesswire.com

    Verisante Technology, Inc. Announces RTO Update:

  • accesswire.com

    Verisante Technology, Inc. Announces Update to Proposed RTO with SunRegen Healthcare AG

  • accesswire.com

    Verisante Technology, Inc. Announces Proposed RTO with SunRegen Healthcare AG

  • accesswire.com

    Verisante Technology, Inc. Announces Exchange Acceptance of Shares for Debt Transaction

  • accesswire.com

    Verisante Technology, Inc. Announces Shares for Debt Agreements

  • accesswire.com

    Verisante Technology, Inc. Announces 2023 AGM Results

  • accesswire.com

    Verisante Technology, Inc. Announces Exchange Approval for Shares for Debt Transaction